Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) P/B ratio
As of 25 September 2026, Johnson & Johnson (JNJ) trades at a P/B ratio of 7.7×. Over the past ten years it has ranged from 3.5× (August 2015) to 7.9× (September 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.5×.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 6.1× | 25.46% |
| FY2024 | 4.9× | (17.36%) |
| FY2023 | 5.9× | (3.24%) |
| FY2022 | 6.1× | 0.13% |
| FY2021 | 6.1× | (7.10%) |
| FY2020 | 6.5× | 0.93% |
| FY2019 | 6.5× | 12.03% |
| FY2018 | 5.8× | (7.04%) |
| FY2017 | 6.2× | 42.98% |
| FY2016 | 4.4× | 9.51% |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 7.2× | (0.78%) |
| Mar 2026 | 7.3× | 18.70% |
| Dec 2025 | 6.1× | 8.47% |
| Sep 2025 | 5.6× | 20.26% |
| 42 more quarters | Free account |
Against its own ten years
Low 3.5×
High 7.9×
Ten-year median
5.7×
Current reading's percentile
100
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ABBV AbbVie Inc. compare | n/m |
| PFE Pfizer Inc. compare | 1.9× |
| AZN AstraZeneca PLC compare | 5.1× |
| NVS Novartis AG compare | 6.6× |
| JNJ Johnson & Johnson | 7.7× |
| MRK Merck & Co., Inc. compare | 8.8× |
| GILD Gilead Sciences, Inc. compare | 16.0× |
| AMGN Amgen Inc. compare | 19.2× |
| LLY Eli Lilly and Company compare | 31.2× |
| Drug Manufacturers General industry median | 5.0× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement